Kappa/Lambda light-chain typing in Alzheimer's Disease.

IF 1.8 4区医学 Q3 CLINICAL NEUROLOGY

Current Alzheimer research Pub Date : 2022-01-01 DOI:10.2174/1567205019666220131101334

Zelal Zuhal Kaya, Mete Bora Tuzuner, Betul Sahin, Emel Akgun, Fehime Aksungar, Sebile Koca, Muhittin Serdar, Sevki Sahin, Nilgun Cinar, Sibel Karsidag, Hasmet Ayhan Hanagasi, Meltem Kilercik, Mustafa Serteser, Ahmet Tari K Baykal

{"title":"Kappa/Lambda light-chain typing in Alzheimer's Disease.","authors":"Zelal Zuhal Kaya, Mete Bora Tuzuner, Betul Sahin, Emel Akgun, Fehime Aksungar, Sebile Koca, Muhittin Serdar, Sevki Sahin, Nilgun Cinar, Sibel Karsidag, Hasmet Ayhan Hanagasi, Meltem Kilercik, Mustafa Serteser, Ahmet Tari K Baykal","doi":"10.2174/1567205019666220131101334","DOIUrl":null,"url":null,"abstract":"Background: Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory loss and cognitive impairment. The diagnosis of Alzheimer's disease according to symptomatic events is still a puzzling task. Developing a biomarker-based, low-cost, and high-throughput test, readily applicable in clinical laboratories, dramatically impacts the rapid and reliable detection of the disease.Objective: This study aimed to develop an accurate, sensitive, and reliable screening tool for diagnosing Alzheimer's disease, which can significantly reduce the cost and time of existing methods.Methods: We have employed a MALDI-TOF-MS-based methodology combined with a microaffinity chromatography enrichment approach using affinity capture resins to determine serum kappa (κ) and lambda (λ) light chain levels in control and patients with AD.Results: We observed a statistically significant difference in the kappa light chain over lambda light chain (κLC/λLC) ratios between patients with AD and controls (mean difference -0,409; % 95 CI:- 0.547 to -0.269; p<0.001). Our method demonstrated higher sensitivity (100.00%) and specificity (71.43%) for discrimination between AD and controls.Conclusion: We have developed a high-throughput screening test with a novel sample enrichment method for determining κLC/λLC ratios associated with AD diagnosis. Following further validation, we believe our test has the potential for clinical laboratories.","PeriodicalId":10810,"journal":{"name":"Current Alzheimer research","volume":"19 1","pages":"84-93"},"PeriodicalIF":1.8000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Alzheimer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1567205019666220131101334","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Background: Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory loss and cognitive impairment. The diagnosis of Alzheimer's disease according to symptomatic events is still a puzzling task. Developing a biomarker-based, low-cost, and high-throughput test, readily applicable in clinical laboratories, dramatically impacts the rapid and reliable detection of the disease.

Objective: This study aimed to develop an accurate, sensitive, and reliable screening tool for diagnosing Alzheimer's disease, which can significantly reduce the cost and time of existing methods.

Methods: We have employed a MALDI-TOF-MS-based methodology combined with a microaffinity chromatography enrichment approach using affinity capture resins to determine serum kappa (κ) and lambda (λ) light chain levels in control and patients with AD.

Results: We observed a statistically significant difference in the kappa light chain over lambda light chain (κLC/λLC) ratios between patients with AD and controls (mean difference -0,409; % 95 CI:- 0.547 to -0.269; p<0.001). Our method demonstrated higher sensitivity (100.00%) and specificity (71.43%) for discrimination between AD and controls.

Conclusion: We have developed a high-throughput screening test with a novel sample enrichment method for determining κLC/λLC ratios associated with AD diagnosis. Following further validation, we believe our test has the potential for clinical laboratories.

查看原文本刊更多论文

阿尔茨海默病的Kappa/Lambda轻链分型

背景:阿尔茨海默病是一种以记忆丧失和认知障碍为特征的进行性神经退行性疾病。根据症状事件诊断阿尔茨海默病仍然是一项令人困惑的任务。开发一种基于生物标志物、低成本、高通量、易于应用于临床实验室的检测方法，将极大地影响疾病的快速、可靠检测。目的:本研究旨在开发一种准确、灵敏、可靠的阿尔茨海默病诊断筛查工具，显著降低现有方法的成本和时间。方法:我们采用基于maldi - tof - ms的方法，结合使用亲和捕获树脂的微亲和层析富集方法，测定对照组和AD患者血清kappa (κ)和lambda (λ)轻链水平。结果:我们观察到AD患者与对照组kappa轻链/λ轻链(κLC/λLC)比值差异有统计学意义(平均差-0,409;% 95 CI:- 0.547 ~ -0.269;结论:我们开发了一种高通量筛选试验，采用一种新的样品富集方法来确定与AD诊断相关的κLC/λLC比率。经过进一步的验证，我们相信我们的测试具有临床实验室的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Alzheimer research 医学-神经科学

CiteScore

4.00

自引率

4.80%

发文量

审稿时长

4-8 weeks

期刊介绍： Current Alzheimer Research publishes peer-reviewed frontier review, research, drug clinical trial studies and letter articles on all areas of Alzheimer’s disease. This multidisciplinary journal will help in understanding the neurobiology, genetics, pathogenesis, and treatment strategies of Alzheimer’s disease. The journal publishes objective reviews written by experts and leaders actively engaged in research using cellular, molecular, and animal models. The journal also covers original articles on recent research in fast emerging areas of molecular diagnostics, brain imaging, drug development and discovery, and clinical aspects of Alzheimer’s disease. Manuscripts are encouraged that relate to the synergistic mechanism of Alzheimer''s disease with other dementia and neurodegenerative disorders. Book reviews, meeting reports and letters-to-the-editor are also published. The journal is essential reading for researchers, educators and physicians with interest in age-related dementia and Alzheimer’s disease. Current Alzheimer Research provides a comprehensive ''bird''s-eye view'' of the current state of Alzheimer''s research for neuroscientists, clinicians, health science planners, granting, caregivers and families of this devastating disease.